Strategic Focus Target customers: biotechnology and gene-editing institutes, university-affiliated research centers, and contract research organizations in need of advanced CRISPR delivery solutions, particularly those pursuing Duchenne Muscular Dystrophy and other genetic diseases.

Collaborative Growth Leverage ongoing partnerships such as the Strongest Hearts Foundation to expand co-development opportunities in muscular dystrophy programs and explore additional disease areas where 2-for-1 AAV delivery could offer a competitive edge.

Funding Signals Seed financing achievement indicates investor interest in innovative delivery platforms; pursue conversations with biotech funds and grant-focused programs to secure non-dilutive or strategic funding for joint development.

Clinical Fit Demonstrated focus on Duchenne and Becker muscular dystrophies positions the company to align with hospitals and health systems that prioritize neuromuscular therapies, enabling pilot collaborations and potential access to clinical trial networks.

Operational Readiness Small team with Cambridge base suggests a nimble partner for joint development, offering tight collaboration cycles; propose Co-Development Partnerships, technology licensing, or sponsored research agreements with larger academic medical centers and regional networks.